Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models
暂无分享,去创建一个
Harvey Wong | H. Wong | Louis Lin | Louis Lin
[1] Utilizing physiologically based pharmacokinetic modeling to inform formulation and clinical development for a compound with pH-dependent solubility. , 2015, Journal of pharmaceutical sciences.
[2] K. Higaki,et al. Prediction of the Plasma Concentration Profiles of Orally Administered Drugs in Rats on the Basis of Gastrointestinal Transit Kinetics and Absorbability , 1997, The Journal of pharmacy and pharmacology.
[3] Ayman El-Kattan,et al. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. , 2007, Expert opinion on drug metabolism & toxicology.
[4] M. Kataoka,et al. Analysis of Intra- and Intersubject Variability in Oral Drug Absorption in Human Bioequivalence Studies of 113 Generic Products. , 2015, Molecular pharmaceutics.
[5] Malcolm Rowland,et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. , 2011, Journal of pharmaceutical sciences.
[6] T. Baillie,et al. Extrapolation of Diclofenac Clearance from in Vitro Microsomal Metabolism Data: Role of Acyl Glucuronidation and Sequential Oxidative Metabolism of the Acyl Glucuronide , 2002, Journal of Pharmacology and Experimental Therapeutics.
[7] R. M. Owen,et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.
[8] X. Chu,et al. Species differences in drug transporters and implications for translating preclinical findings to humans , 2013, Expert opinion on drug metabolism & toxicology.
[9] D. Flanagan,et al. General solution for diffusion-controlled dissolution of spherical particles. 1. Theory. , 1999, Journal of pharmaceutical sciences.
[10] Hywel D Williams,et al. Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.
[11] J. Dressman,et al. Mixing-tank model for predicting dissolution rate control or oral absorption. , 1986, Journal of pharmaceutical sciences.
[12] Gordon L Amidon,et al. A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.
[13] Yuichi Sugiyama,et al. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. , 2009, Drug metabolism and pharmacokinetics.
[14] Lawrence X. Yu,et al. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans , 1996 .
[15] Gordon L. Amidon,et al. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon , 1987, Journal of Pharmacokinetics and Biopharmaceutics.
[16] J. Dressman,et al. Estimating drug solubility in the gastrointestinal tract. , 2007, Advanced drug delivery reviews.
[17] Michael Gertz,et al. Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction , 2011, Drug Metabolism and Disposition.
[18] Torsten Teorell,et al. Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .
[19] C. Prakash,et al. Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist , 2015, Drug Metabolism and Disposition.
[20] Xiaomei Zhuang,et al. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA‐14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction , 2014, Biopharmaceutics & drug disposition.
[21] Keith W. Ward,et al. Optimizing Pharmacokinetic Properties and Attaining Candidate Selection , 2012 .
[22] J.M. Bailey,et al. A simple analytical solution to the three-compartment pharmacokinetic model suitable for computer-controlled infusion pumps , 1991, IEEE Transactions on Biomedical Engineering.
[23] T. Mano,et al. Solubility and dissolution profile assessment in drug discovery. , 2007, Drug metabolism and pharmacokinetics.
[24] G. Amidon,et al. Physiological parameters for oral delivery and in vitro testing. , 2010, Molecular pharmaceutics.
[25] Xavier Pepin,et al. Mechanistic investigation of the negative food effect of modified release zolpidem , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[26] L. Benet,et al. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.
[27] G. Amidon,et al. Physicochemical model for dose-dependent drug absorption. , 1984, Journal of pharmaceutical sciences.
[28] P. Welling,et al. Effects of food on drug absorption. , 1989, Pharmacology & therapeutics.
[29] Po-Chang Chiang,et al. Incorporation of Physiologically Based Pharmacokinetic Modeling in the Evaluation of Solubility Requirements for the Salt Selection Process: A Case Study Using Phenytoin , 2013, The AAPS Journal.
[30] K. Maeda,et al. Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.
[31] M. Jamei,et al. A Novel Physiologically-Based Mechanistic ModelPredicting Oral Drug Absorption: The Advanced Dissolution, Absorption, and Metabolism (ADAM) Model , 2007 .
[32] Lin Yang,et al. Mechanistic prediction of food effects for Compound A tablet using PBPK model , 2017, Saudi journal of biological sciences.
[33] A. Glomme,et al. Predicting the Intestinal Solubility of Poorly Soluble Drugs , 2007 .
[34] Y Zhang,et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. , 1998, Journal of pharmaceutical sciences.
[35] T. Murakami,et al. Intestinal efflux transporters and drug absorption. , 2008, Expert opinion on drug metabolism & toxicology.
[36] Morton B. Brown,et al. Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.
[37] G. Amidon,et al. Description and simulation of a multiple mixing tank model to predict the effect of bile sequestrants on bile salt excretion. , 1993, Journal of pharmaceutical sciences.
[38] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[39] B Agoram,et al. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.
[40] Kevin C. Johnson,et al. Guidance in the Setting of Drug Particle Size Specifications to Minimize Variability in Absorption , 1996, Pharmaceutical Research.
[41] Lawrence X. Yu. An Integrated Model for Determining Causes of Poor Oral Drug Absorption , 1999, Pharmaceutical Research.
[42] Neil Parrott,et al. Applications of physiologically based absorption models in drug discovery and development. , 2008, Molecular pharmaceutics.
[43] John P. Rose,et al. Developability assessment of clinical drug products with maximum absorbable doses. , 2012, International journal of pharmaceutics.
[44] B. Hirst,et al. P-glycoprotein Potentiates CYP3A4-mediated Drug Disappearance during Caco-2 Intestinal Secretory Detoxification , 2004, Journal of drug targeting.
[45] R. Upton,et al. Food, gastrointestinal pH, and models of oral drug absorption , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[46] G. Amidon,et al. Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.
[47] A. Noyes,et al. The rate of solution of solid substances in their own solutions , 1897 .
[48] H Lennernäs,et al. Membrane transport of drugs in different regions of the intestinal tract of the rat. , 1998, Journal of pharmaceutical sciences.
[49] M. Paine,et al. P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine , 2003, Pharmaceutical Research.
[50] Lawrence X. Yu,et al. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. , 2004, Current opinion in drug discovery & development.
[51] P. Breen,et al. Drug dissolution: significance of physicochemical properties and physiological conditions. , 2013, Drug discovery today.
[52] Hefei Zhang,et al. Application of Physiologically Based Absorption Modeling to Formulation Development of a Low Solubility, Low Permeability Weak Base: Mechanistic Investigation of Food Effect , 2014, AAPS PharmSciTech.